title: Extrapulmonary small cell carcinoma in head and neck.
abstract: OBJECTIVE
  The management of extrapulmonary small cell carcinoma has not been standardised to date. This study reviewed the clinical course, management and survival outcomes of patients with extrapulmonary small cell carcinoma in the head and neck region.
  
  
  METHODS
  Nine patients with extrapulmonary small cell carcinoma in the head and neck were included in this study.
  
  
  RESULTS
  Five patients received radical surgery followed by adjuvant chemotherapy or radiotherapy or both. Two other patients were treated with chemotherapy consisting of CPT11 plus cisplatin or CPT11 plus cisplatin plus VP-16 three times. Two other patients received chemoradiotherapy consisting of S-1 or CPT11 plus cisplatin. The median overall survival was 14.5 months, with a three-year survival rate of 23.7 per cent.
  
  
  CONCLUSIONS
  The prognosis of extrapulmonary small cell carcinoma is generally poor. Further prospective multicentre studies are required for better understanding of disease entities and response to treatment modalities.
authors.affiliation: Department of Otorhinolaryngology,Graduate School of Medical Sciences,Kyushu University,Fukuoka,Japan.
authors.forename: R
authors.initials: R
authors.lastname: Yasumatsu
authors.affiliation: Department of Otorhinolaryngology,Graduate School of Medical Sciences,Kyushu University,Fukuoka,Japan.
authors.forename: T
authors.initials: T
authors.lastname: Nakashima
authors.affiliation: Department of Otorhinolaryngology,Graduate School of Medical Sciences,Kyushu University,Fukuoka,Japan.
authors.forename: M
authors.initials: M
authors.lastname: Yamauchi
authors.affiliation: Department of Otorhinolaryngology,Graduate School of Medical Sciences,Kyushu University,Fukuoka,Japan.
authors.forename: S
authors.initials: S
authors.lastname: Toh
authors.affiliation: Department of Otorhinolaryngology,Graduate School of Medical Sciences,Kyushu University,Fukuoka,Japan.
authors.forename: S
authors.initials: S
authors.lastname: Komune
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D018288:Carcinoma, Small Cell / Q000401:mortality* / Q000628:therapy*; D059248:Chemoradiotherapy; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D018450:Disease Progression; D004338:Drug Combinations; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006258:Head and Neck Neoplasms / Q000401:mortality* / Q000628:therapy*; D006801:Humans; D000077146:Irinotecan; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000008:administration & dosage; D018714:Radiotherapy, Adjuvant; D015996:Survival Rate; D005641:Tegafur / Q000008:administration & dosage
chemical_list: D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D005047:Etoposide; D000077146:Irinotecan; D002945:Cisplatin; D002166:Camptothecin
keywords: Treatment